Children's oncology Group's 2013 blueprint for research: Acute lymphoblastic leukemia

Stephen P. Hunger; Mignon L. Loh; James A. Whitlock; Naomi J. Winick; William L. Carroll; Meenakshi Devidas; Elizabeth A. Raetz

doi:10.1002/pbc.24420

Children's oncology Group's 2013 blueprint for research: Acute lymphoblastic leukemia

Stephen P. Hunger, Mignon L. Loh, James A. Whitlock, Naomi J. Winick, William L. Carroll, Meenakshi Devidas, Elizabeth A. Raetz

Research output: Contribution to journal › Review article › peer-review

143 Scopus citations

Abstract

Approximately 90% of the 2,000 children, adolescents, and young adults enrolled each year in Children's Oncology Group acute lymphoblastic leukemia (ALL) trials will be cured. However, high-risk subsets with significantly inferior survival remain, including infants, newly diagnosed patients with age ≥10 years, white blood count ≥50,000/μl, poor early response or T-cell ALL, and relapsed ALL patients. Effective strategies to improve survival include better risk stratification, optimizing standard chemotherapy and combining targeted therapies with cytotoxic chemotherapy, the latter of which is dependent upon identification of key driver mutations present in ALL.

Original language	English (US)
Pages (from-to)	957-963
Number of pages	7
Journal	Pediatric Blood and Cancer
Volume	60
Issue number	6
DOIs	https://doi.org/10.1002/pbc.24420
State	Published - Jun 2013

Keywords

Acute lymphoblastic leukemia (ALL)
COG ALL trials

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Hematology
Oncology

Access to Document

10.1002/pbc.24420

Cite this

@article{d69b91554d834e3fa20db028322d5d4e,

title = "Children's oncology Group's 2013 blueprint for research: Acute lymphoblastic leukemia",

abstract = "Approximately 90% of the 2,000 children, adolescents, and young adults enrolled each year in Children's Oncology Group acute lymphoblastic leukemia (ALL) trials will be cured. However, high-risk subsets with significantly inferior survival remain, including infants, newly diagnosed patients with age ≥10 years, white blood count ≥50,000/μl, poor early response or T-cell ALL, and relapsed ALL patients. Effective strategies to improve survival include better risk stratification, optimizing standard chemotherapy and combining targeted therapies with cytotoxic chemotherapy, the latter of which is dependent upon identification of key driver mutations present in ALL.",

keywords = "Acute lymphoblastic leukemia (ALL), COG ALL trials",

author = "Hunger, {Stephen P.} and Loh, {Mignon L.} and Whitlock, {James A.} and Winick, {Naomi J.} and Carroll, {William L.} and Meenakshi Devidas and Raetz, {Elizabeth A.}",

year = "2013",

month = jun,

doi = "10.1002/pbc.24420",

language = "English (US)",

volume = "60",

pages = "957--963",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "6",

}

TY - JOUR

T1 - Children's oncology Group's 2013 blueprint for research

T2 - Acute lymphoblastic leukemia

AU - Hunger, Stephen P.

AU - Loh, Mignon L.

AU - Whitlock, James A.

AU - Winick, Naomi J.

AU - Carroll, William L.

AU - Devidas, Meenakshi

AU - Raetz, Elizabeth A.

PY - 2013/6

Y1 - 2013/6

N2 - Approximately 90% of the 2,000 children, adolescents, and young adults enrolled each year in Children's Oncology Group acute lymphoblastic leukemia (ALL) trials will be cured. However, high-risk subsets with significantly inferior survival remain, including infants, newly diagnosed patients with age ≥10 years, white blood count ≥50,000/μl, poor early response or T-cell ALL, and relapsed ALL patients. Effective strategies to improve survival include better risk stratification, optimizing standard chemotherapy and combining targeted therapies with cytotoxic chemotherapy, the latter of which is dependent upon identification of key driver mutations present in ALL.

AB - Approximately 90% of the 2,000 children, adolescents, and young adults enrolled each year in Children's Oncology Group acute lymphoblastic leukemia (ALL) trials will be cured. However, high-risk subsets with significantly inferior survival remain, including infants, newly diagnosed patients with age ≥10 years, white blood count ≥50,000/μl, poor early response or T-cell ALL, and relapsed ALL patients. Effective strategies to improve survival include better risk stratification, optimizing standard chemotherapy and combining targeted therapies with cytotoxic chemotherapy, the latter of which is dependent upon identification of key driver mutations present in ALL.

KW - Acute lymphoblastic leukemia (ALL)

KW - COG ALL trials

UR - http://www.scopus.com/inward/record.url?scp=84876442551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876442551&partnerID=8YFLogxK

U2 - 10.1002/pbc.24420

DO - 10.1002/pbc.24420

M3 - Review article

C2 - 23255467

AN - SCOPUS:84876442551

SN - 1545-5009

VL - 60

SP - 957

EP - 963

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 6

ER -

Children's oncology Group's 2013 blueprint for research: Acute lymphoblastic leukemia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this